(Q80397888)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric Model (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

relapsing-remitting multiple sclerosis

1 reference

Claude Lepen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Patricia Coyle

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Timothy Vollmer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Lance Blumhardt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Hervé Lilliu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ariel Beresniak

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

Clinical Drug Investigation

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

571-581

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

31 December 2019

cites work

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

A FALLACY OF THE MULTIPLICATIVE QALY MODEL FOR LOW-QUALITY WEIGHTS IN STUDENTS AND PATIENTS JUDGING HYPOTHETICAL HEALTH STATES

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Life expectancy in patients attending multiple sclerosis clinics

1 reference

12 December 2020

Economic Evaluation of Multiple Sclerosis in the UK, Germany and France

1 reference

12 December 2020

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

1 reference

12 December 2020

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

12 December 2020

10.2165/00044011-200323090-00003

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17535070%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference